AVXL (Anavex Life Sciences) Short Percentage of Float


AVXL Anavex Life Sciences Corp AVXL
31 GF Score
Price $2.62
! 1 Warning Sign
View Full Analysis

What is Anavex Life Sciences Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

AVXL vs ZNTL, HUMA, SABS: Short Percentage of Float Comparison

For the Biotechnology subindustry, Anavex Life Sciences's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anavex Life Sciences Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's Short Percentage of Float falls into.


AVXL
31GF Score
Anavex Life Sciences Corp AVXL
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anavex Life Sciences Business Description

Other Exchanges 0HFR:UK12X1:Germany
Address 630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
31GF Score

Get the complete analysis for AVXL

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.62
Price